PROCEPT BioRobotics (PRCT) Competitors

Atrion (NASDAQ:ATRI) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Is ATRI or PRCT more profitable?

Atrion has a net margin of 10.60% compared to Atrion's net margin of -66.12%. PROCEPT BioRobotics' return on equity of 7.75% beat Atrion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrion	10.60%	7.75%	7.12%
PROCEPT BioRobotics	-66.12%	-41.35%	-27.92%

Do analysts recommend ATRI or PRCT?

PROCEPT BioRobotics has a consensus target price of $61.20, suggesting a potential downside of 7.83%. Given Atrion's higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Atrion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrion	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
PROCEPT BioRobotics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in ATRI or PRCT?

Atrion received 101 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. However, 62.22% of users gave PROCEPT BioRobotics an outperform vote while only 54.89% of users gave Atrion an outperform vote.

Company	Underperform	Outperform
Atrion	Outperform Votes 129 54.89%	Underperform Votes 106 45.11%
PROCEPT BioRobotics	Outperform Votes 28 62.22%	Underperform Votes 17 37.78%

Which has more volatility & risk, ATRI or PRCT?

Atrion has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Which has preferable earnings and valuation, ATRI or PRCT?

Atrion has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrion	$169.33M	4.78	$19.41M	$10.64	43.26
PROCEPT BioRobotics	$136.19M	25.07	-$105.90M	-$2.12	-31.32

Does the media favor ATRI or PRCT?

In the previous week, Atrion had 2 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 10 mentions for Atrion and 8 mentions for PROCEPT BioRobotics. Atrion's average media sentiment score of 1.30 beat PROCEPT BioRobotics' score of 0.22 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atrion	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PROCEPT BioRobotics	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders hold more shares of ATRI or PRCT?

66.2% of Atrion shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 22.8% of Atrion shares are owned by insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Atrion beats PROCEPT BioRobotics on 10 of the 17 factors compared between the two stocks.